Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Oncopeptides AB ( (SE:ONCO) ) has issued an announcement.
Oncopeptides reported a strong start to 2026, with first-quarter net sales rising 91 percent year-on-year to SEK 25.4 million, driven by robust Pepaxti demand in Italy and renewed growth in Germany. Despite an operating loss of SEK 37.5 million and a negative profit after tax, the company improved its earnings versus last year and strengthened liquidity, ending the quarter with SEK 205.2 million in cash.
Strategically, the group announced a rights issue of about SEK 200 million, advanced its R&D pipeline with fast-track status for a glioblastoma study and new NK-cell engager data, and moved to expand Pepaxti’s label to third-line treatment. These steps aim to reinforce Pepaxti’s positioning in multiple myeloma, deepen real-world evidence in Europe, and support Oncopeptides’ transition toward a more commercially driven and financially resilient oncology player.
More about Oncopeptides AB
Oncopeptides AB is a Stockholm-based biotech company focused on developing therapies for difficult-to-treat cancers. Its primary commercial product is Pepaxti, a treatment for multiple myeloma, with a growing commercial presence in key European markets such as Italy and Germany.
Average Trading Volume: 3,305,823
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK494.9M
See more insights into ONCO stock on TipRanks’ Stock Analysis page.